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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic systemic autoim-
mune inflammatory disease displaying joint lesions with
symmetrical chronic progressive aseptic synovitis and
erosive-destructive changes in late stage, and extra-articular
lesions, which are systemic manifestations. RA is a multi-
factorial disease. Despite prolonged studies the role of par-
ticular aetiological factors is still unknown. For a long time
it has been suggested that development of RA might cause
viral infection in genetically predisposed people. Infectious
agents have the potential to initiate auto-reactivity through
polyclonal activation, release of previously sequestered an-
tigens or molecular mimicry. Some studies suggest that mo-
lecular mimicry of host proteins by a pathogen can induce
autoimmune diseases (Lunardi et al., 2005). However, more
commonly viruses induce autoimmunity by cell death, pre-
dominantly by increased apoptosis, resulting in the release
of self-antigens; increased apoptosis indeed has been sug-
gested as a major pathogenic mechanism in autoimmune
connective tissue diseases (Mackay et al., 2008). As RA is a
chronic, progressive disease, it is suspected that it could be
caused by a worldwide-distributed infectious agent.
Severe synovial lining layer hyperplasia, neovascularis-
ation, and inflammatory infiltration of the sublining with
lymphocytes and macrophages develop in the case of RA
(Beaten et al., 2000; Firestein, 2003; Trembleau et al.,
2010; Costenbader et al., 2011). Impaired T lymphocyte ac-
tivation is one of the first changes observed in RA patients.
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Rheumatoid arthritis (RA) is a chronic systemic autoimmune inflammatory disease affecting joints
and causing symmetrical chronic progressive aseptic synovitis and erosive-destructive changes.
Viruses and viral infections are considered to be the main risk factors for autoimmune disease de-
velopment (especially for individuals with genetic predisposition). The goal of this study was to
evaluate the frequency of HHV-6 and HHV-7 persistent infection and its activity phase in RA and
osteoarthritis (OA) patients, and healthy persons. We examined also the influence of HHV-6 and
-7 infections on RA activity, aggressiveness, radiographical stage, and frequency of complica-
tions as well as the presence of HHV-6 infection markers in synovial fluid and synovial tissues of
RA joints of affected patients. Despite the lack of significant correlation between frequency of
persistent single HHV-6, single HHV-7, and concurrent HHV-6 and HHV-7 infection and RA clini-
cal course, we found that both active and latent HHV-6 and/or HHV-7 infection increased RA ac-
tivity and progression in several clinical and laboratory parameters. Regarding the severity of the
course of RA, we observed also a high prevalence of RA complications in the patient group with
active single HHV-6 infection and also a more severe radiographical stage in RA patients with ac-
tive concurrent HHV-6 and HHV-7 infection. Moreover, viral infection markers were found in syno-
vial fluid and synovial tissues of affected joints of RA patients. This suggests that HHV-6 and/or
HHV-7 infection has effect on the disease clinical course, but virus reactivation may be a conse-
quence of immunosuppressive treatment.
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Viral antigens activate development of naive CD4+ T cells
in T cells subclasses, which stimulates macrophages and
monocytes to produce many different inflammatory
cytokines, including IL-1, IL-6, and TNF-, and proteolytic
enzymes. Therefore, destruction of synovium, cartilage and
subchondral bone occurs (Costenbader et al., 2011). There
is an increased level of many different cytokines in serum
and synovial fluid in the case of active RA. TNF- pro-
motes production of osteoclasts and stimulates many cells
and inflammatory cytokines that cause further development
of inflammation (Choy and Panayi, 2001). Several studies
have shown correlation of IL-6 activity and a more active
and more aggressive RA course (Gottenberg et al., 2012).
Several reports based on epidemiological evidence support
the hypothesis that certain viruses, including human herpes-
viruses (HHVs), might be potential triggers of RA develop-
ment. HHV-6 and HHV-7 are classified in the Roseolovirus
genus in the Betaherpesvirinae subfamily. HHV-6 and
HHV-7 are ubiquitous in the general population, with up to
90% of adults being seropositive. Both these viruses are the
causative agents of exanthema subitum. After primary in-
fection, which commonly occurs in early childhood, infec-
tion remains latent/persistent lifelong. HHV-6 and -7 may
become reactivated under conditions of stress, trauma, hor-
monal disbalance and immunosuppression, thus contribut-
ing further toward immunosuppression (Caselli and Luca,
2007; Isegawa et al., 2010). Both viruses infect cells of the
immune system and therefore may modulate their function.
The primary target for HHV-6 and HHV-7 replication is
CD4+ T lymphocytes, pivotal cells in generation of
humoral and cell-mediated adaptive immune response. Both
viruses have been shown to up-regulate TNF- secretion.
HHV-7 might also act as a trigger factor for HHV-6 reacti-
vation (Lusso, 2006; Wang and Pellet, 2007, Prober, 2011).
IL-17 acts synergistically with TNF- and induces the pro-
duction of several inflammatory mediators in the affected
synovium, which are further synergistically enhanced via
combinations of IL-17 with other cytokines (Gonzalez-
Alvaro et al., 2009). IL-17 also promotes the survival of
both the synoviocytes and inflammatory cells and promotes
the maturation of immune cells. This leads to an increased
number of synoviocytes and inflammatory cells in the
synovial fluid and in the synovium, leading to the hyperpla-
sia and exacerbated inflammation observed in joints of RA
patients (Benedetti and Miossec, 2014). To assess the role
of viral infection in RA we evaluated the frequency of
HHV-6 and HHV-7 reactivation in RA patients, osteo-
arthritis (OA) patients and healthy persons. Also we exam-
ined the effect of HHV-6 and -7 infection on RA activity,
aggressiveness, radiological stage and frequency of compli-
cations.
MATERIALS AND METHODS
Patients and controls. RA and OA patients were recruited
from the Rîga East University Hospital Clinic “Linezers”
and Clinic “Gaiïezers” and from the Hospital of Traumatol-
ogy and Orthopaedics. The inclusion criteria were previ-
ously established diagnosis of RA or OA, or primary diag-
nosis of RA or OA established in the given hospitals. All
RA patients fulfilled 1987 American College of Rheumatol-
ogy (ACR) revised classification criteria for RA or the 2010
ACR/EULAR classification criteria for RA. Patients ful-
filled relevant ACR criteria for OA affected joints: wrists
(Altman et al., 1990), hip (Altman et al., 1991) and knee
(Altman et al., 1986). Patients who underwent replacement
surgery fulfilled hip ACR criteria for OA. Pregnant women,
alcoholic patients and patients having any other inflamma-
tory disease were excluded from the study.
The study was performed during 2010–2013 and included
80 RA patients (67 females and 11 males) with mean age
55.8 years (range 19–80) and 78 OA patients (52 females
and 26 males) with mean age 64.6 years (range 35–86) as
well as a cohort of 19 healthy control persons (16 females
and 3 males) with mean age 59.6 years (range 38–89). Sig-
nificantly more males were in the OA patients group than in
the RA group (p = 0.0046; OR 0.3, 95% CI: 0.1 to 0.7). OA
patients were significantly older (p < 0.0001; 95% CI: 4.9 to
12.7) than RA patients; but control individual age did not
significantly differ from that of RA patients (p = 0.3; 95%
CI: –3.0 to 10.7) and OA patients (p = 0.12; 95% CI: –1.8
to 11.7). Early RA with symptoms less than 24 months
(symptoms developed up to 24 months before enrolment in
the study) (Emery, 1994) was detected in 33 RA patients.
Fifty-five RA patients received synthetic and/or biologic
DMARDs (disease modifying antirheumatic drugs). Eight
of them received methotrexate alone, 35 of them — metho-
trexate plus one or more DMARD (hydroxycloroqine, sul-
fasalazine, leflunomide, tocilizumab). Seventeen RA pa-
tients received synthetic DMARDs without methotrexate
and five received biological DMARD tocilizumab with or
without methotrexate.
The clinical features, treatment and laboratory parameters
[haemoglobin, C reactive protein (CPR), rheumatoid factor
(RF) and anti-cyclic citrullinated peptide (anti-CCP)], and
disease activity score DAS28 (only for RA patients) were
examined for their potential association with HHV-6 and
HHV-7 infections.
Physical examination. Clinical examination of RA patients
included assessment of morning stiffness along with swel-
ling and tenderness of joints, and development of RA com-
plications. Full physical examination was performed, and
swollen and painful joints were recorded; of the 68 joints
examined, 28 were used for DAS28 calculation (Arnett et
al., 1988). DAS28 is a composite index that consists of the
number of swollen and painful joints of 28 joints examined
by a doctor, patient's general health assessment in visual
analogue scale and CRP level in the last blood sample. The
disease activity score for RA patients was used as a disease
activity indicator. The following RA complications were re-
corded: polyneuropathy, myopathy, sicca syndrome, and
rheumatoid nodules, damage of cervical vertebrae, osteopo-
rosis and scleritis.
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Radiological examination of bone structure. Plain radiog-
raphy was used for RA diagnosis (van der Heijde, 1996).
However, only the late signs of preceding disease activity
can be visualised by radiography. Magnetic resonance im-
aging (MRI) can detect RA erosive change with greater sen-
sitivity than conventional radiography (Sommer et al.,
2005). Therefore, MRI was used to precisely determine
early changes and erosions in wrists. MRI protocols FSE T2
„fat sat” coronal plane, GR axial plane, SE T1 „fat sat” co-
ronal plane post gadolinium, 3D SPGR coronal plane post
gadolinium were used. MRI test read-out included assess-
ment of synovitis, bone oedema, and bone erosion. Staging
was based on Venables and Wheeless recommendations
(Wheeless, 2012; Venables and Maini, 2013).
Sample collection and preparation. EDTA anti-coagulat-
ed peripheral blood, synovial tissues and synovial fluid
samples from RA and OA patients and EDTA anti-
coagulated peripheral blood samples from apparently
healthy persons were collected. Plasma samples were sepa-
rated from peripheral blood by centrifugation.
DNA was isolated from whole blood, cell-free blood
plasma, synovial tissues and synovial fluid by standard phe-
nol-chloroform extraction. Before DNA extraction, plasma
and synovial fluid samples were treated with DNase I. To
assure the quality of the whole blood and synovial tissue
DNA, as well as to exclude contamination of plasma and
synovial fluid DNA by cellular DNA debris, a beta-globin
PCR was carried out.
Laboratory analysis of disease activity. The level of CRP
and erythrocyte sedimentation rate (ESR) served as markers
of RA and OA activity. ESR higher than 30 mm/h and CRP
level above 8 mg/L were considered as elevated.
CRP or ESR can be used for DAS28 calculation. In our case
CRP was used for calculation of DAS28, because it more
corresponds to ongoing inflammation. RA patients were
classified as in remission (DAS28 score  2.6), low disease
activity (DAS28 score 2.6  3.2), moderate disease activity
(DAS28 score 3.2–5.1) or severe disease activity (DAS28
score  5.1).
Laboratory analysis of disease aggressiveness. RF and
anti-CCP were analysed as markers of RA aggressiveness.
For RA diagnosis we used RF with or without anti-CCP. RF
has sensitivity 31–54% and specificity 92–93% for RA di-
agnosis, and anti-CCP has sensitivity 39–50% and specific-
ity 93–97% (Niewold et al., 2007). Previous studies have
shown that the anti-CCP test is positive in about 1% of the
healthy population (Zendman et al., 2006; Nam et al., 2015)
and up to 8% of OA patients (Sauerland et al., 2005). RF
and anti-CCP antibodies were detected also in OA patients.
An RF level higher than 14 U/ml and anti-CCP antibody
level higher than 17 U/ml were considered as positive. Clin-
ical course of RA was classified by RF as non-aggressive if
RF  14 U/ml, low aggressive if RF 14  42 U/ml, highly
aggressive if RF > 42 U/ml and very aggressive if RF >
1000 U/ml. The clinical course of RA was classified also
by anti-CCP antibody level in four aggressiveness groups:
non-aggressive (anti-CCP  17 U/ml), low aggressive
(anti-CCP 17  51 U/ml), highly aggressive (anti-CCP > 51
U/ml) and very aggressive RA (anti-CCP > 1000 U/ml).
Detection of TNF-a, IL-6 and IL-17 levels. The levels of
TNF-, IL-6 and IL-17 were measured by enzyme-linked
immunosorbent assay (ELISA) (TNF-, IL-6 by Nordic
Biosite, Denmark and IL-17 by R&D systems, USA) and
analysed in comparison with the presence or absence of
HHV-6 and HHV-7 infection markers.
Determination of HHV-6 and HHV-7 genomic se-
quences. One microgram of whole blood and synovial tis-
sue DNA as well as 10 µl of plasma and synovial fluid
DNA was subjected to nested PCR (nPCR) with HHV-6
and HHV-7 specific primers as described previously (Ber-
neman et al., 1992; Secchiero et al., 1995). HHV-6 and
HHV-7 positive and negative DNAs as well as water con-
trols were included in each experiment. Detection of viral
DNA in cell-associated material (whole blood and synovial
tissues) has been used as a marker of persistent infection,
while detection of viral DNA in cell-free blood plasma and
synovial fluid as a marker of active infection (virus reacti-
vation). The number of persons with latent infection was
calculated as the difference between numbers with persis-
tent and active infection.
Synovial histopathology and immunohistochemistry.
Synovial tissues were obtained by open biopsy during elec-
tive replacement of hip without USG guide. Biopsies were
performed more often in OA patients because they more of-
ten underwent joint replacement surgery. Synovial tissues
were obtained from 7 RA and 54 OA patients. Of them, tis-
sue samples from six RA and 43 OA patients were fixed in
formalin and embedded in paraffin. Thereafter, paraffin-
embedded tissue sections were stained with haematoxylin
and eosin for routine histopathological analysis, which in-
cluded evaluation of synovial lining layer thickness, vascu-
larity of the sublining layer, inflammatory infiltration of the
sublining layer, and presence of lymphoid aggregates and
plasma cells, as recommended by Baeten et al. (2003) and
Kruithof et al. (2005). Consecutive synovial tissue sections
obtained routinely were utilised for immunohistochemistry.
Immunohistochemical reactions detecting A and B strains
were performed using anti-HHV-6 (2001) sc-65463 mono-
clonal antibody raised against viral lysate (Santa Cruz Bio-
technology, Inc., Santa Cruz, CA, USA, 1:200 dilution).
Synovial CD68+ macrophages were detected by mono-
clonal mouse anti-human CD68 (DakoCytomation, Glos-
trup, Denmark, 1:100 dilution, clone PG-M1), which labels
monocytes and macrophages through recognition of lysoso-
mal glycoprotein/plasma membrane proteins. For visualisa-
tion of reaction results, a HiDef Detection™ HRP Polymer
system (CellMarque, Rocklin, CA, USA) and DAB+Chro-
mogen (Cell Marque, Rocklin, CA, USA) was used. Immu-
nohistochemical controls included omission of the primary
antibody and sections from tonsil were used as a positive
control for CD68. Tissue sections were analysed using an
appropriate magnification (from ×100 up to ×400), and im-
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ages were produced with a digital camera DFC 450C on a
Leitz DMRB bright-field microscope.
Statistical analysis. Data were analysed using SPSS and
GraphPad Prism 6.0 software. Statistical differences in the
detection of frequency of HHV-6 and/or HHV-7 genomic
sequences in the extracted DNA samples of the individuals
with RA and OA as well as the control group persons were
assessed with the Fisher’s exact test and T-test. The mean
values of all clinical parameters and plasma cytokines levels
were expressed as median with variance characterised by
the interquartile region (IQR). Significance of differences
between medians was assessed using the nonparametric
Mann Whitney U test. Statistical significance was set at
p < 0.05.
The local Ethics Committee approved the study and signed
informed consent was obtained from participating patients.
RESULTS
Frequency of persistent HHV-6 and HHV-7 infection.
Persistent HHV-6 and/or HHV-7 infection was observed in
67 of 80 (83.8%) RA patients, 63/78 (80.8%) OA patients
and in 15/19 (78.9%) control individuals. Among RA pa-
tients with persistent HHV-6 and/or -7 infection, 6/67
(9.0%) had single HHV-6 infection, 42/67 (62.7%) — sin-
gle HHV-7 infection, and 19/67 (28.4%) — concurrent
HHV-6 and HHV-7 infection. Among OA patients with per-
sistent HHV-6 and/or -7 infection, single HHV-6 infection
was detected in one of 63 patients (1.6%), single HHV-7 in-
fection in 41/63 (65.1%) and concurrent HHV-6 and
HHV-7 infection in 21/63 (33.3%) patients. Prevalence of
single HHV-6, single HHV-7 and concurrent HHV-6 and
HHV-7 persistent infection among healthy control persons
was 0/15 (0%), 10/15 (66.7%) and 5/15 (33.3%), respec-
tively (Table 1).
Frequency of HHV-6 and HHV-7 reactivation. All sam-
ples of patients and healthy persons with HHV-6 and/or
HHV-7 genomic sequences in whole blood DNA (marker of
persistent viral infection) were analysed for viral infection
reactivation (viral genomic sequences in cell-free blood
plasma DNA). HHV-6 reactivation was detected in 10/67
RA (14.9%), in 16/63 (25.4%) OA, and in 4/15 (26.7%)
healthy persons with persistent HHV-6 and/or HHV-7 in-
fection. The overall frequency of viral infection reactivation
was 10/80 RA (12.5%), 16/78 (20.5%) OA patients, and
4/19 (21.1%) healthy control persons Single HHV-6 reacti-
vation was observed in 8/25 (32.0%) RA patients with
HHV-6 persistent infection [2/6 (66.6%) with single
HHV-6, and 6/19 (31.6%) with concurrent HHV-6 and
HHV-7 infection] and in 9/22 (40.9%) OA patients [1/1
with single HHV-6 infection and 8/21 (38.1%) with concur-
rent HHV-6 and HHV-7 infection] as well as in 3/5 (60.0%)
control group individuals with concurrent HHV-6 and
HHV-7 infection. HHV-7 reactivation was detected in
13/67 RA (19.4%), in 14/63 (22.2%) OA, and in 3/15 (20%)
healthy persons with persistent HHV-6 and/or HHV-7 in-
fection. Calculated for the whole group, HHV-7 reactivation
occurred in 13/80 (16.3%) RA patients, 14/78 (17.9%) OA
patients as well as in 3/19 (15.8%) healthy control persons.
Single HHV-7 reactivation was found in 11/61 (18.0%) RA
patients with HHV-7 persistent infection [11/42 (26.2%)
with single HHV-7 infection and in none from the 19 in
concurrent infection group], in 7/62 (11.3%) OA patients
[7/41 (17.1%) with single HHV-7 infection, in none of the
21 in the concurrent infection group] as well as in 2/15
(13.3%) control group individuals [2/10 (20%) with single
HHV-7 infection, none from the 5 patients in the concurrent
infection group]. Simultaneous HHV-6 and HHV-7 reacti-
vation was observed in 2/19 (10.5%) RA, in 7/21 (33.3%)
OA patients and in 1/5 (20%) healthy persons with concur-
rent HHV-6 and HHV-7 persistent infection (Table 1).
Frequency of HHV-6 and HHV-7 latent infection. There
were no OA patients and healthy persons with single latent
HHV-6 infection, but latent HHV-6 infection was detected
in 4/6 (66.7%) RA patients. Latent HHV-7 infection was
observed in 31/42 (73.8%) RA, in 34/41 (82.9%) OA pa-
tients and in 8/10 (80.0%) control group individuals with
persistent single HHV-7 infection. Latent concurrent
HHV-6 and HHV-7 infection was detected in 11/19 (57.9%)
RA, in 6/21 (28.6%) OA patients, and 1/5 (20%) healthy
person with persistent concurrent HHV-6 and HHV-7 infec-
tion.
Presence of HHV-6 and HHV-7 DNA in synovial fluid.
HHV-6 and/or HHV-7 genomic sequences were also found
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in synovial fluid DNA of 5/6 (83.3%) RA and 13/34
(38.2%) OA patients. A single HHV-6 genomic sequence
was detected in synovial fluid DNA samples of 2/6 (33.3%)
RA patients, and in none of the OA patients (p = 0.0192;
OR 38.3, 95% CI: 1.6 to 932.3), while a single HHV-7 ge-
nomic sequence was present in synovial fluid DNA samples
of 2/6 (33.3%) RA and 10/34 (29.4%) OA patients. Ge-
nomic sequences of both viruses were detected in synovial
fluid DNA samples of 1/6 (16.7%) RA and 3/34 (8.8%) OA
patients (Table 2).
Presence of HHV-6 and HHV-7 DNA in synovial tissues.
HHV-6 and/or HHV-7 genomic sequences were detected in
synovial tissue DNA samples of 4/7 RA (57.1%) and 20/54
(37.0%) OA patients. A single HHV-6 sequence was not de-
tected in any of the synovial tissue DNA samples from RA
and OA patients. A single HHV-7 genomic sequence was
found in 1/7 (14.3%) RA and in 17/54 (31.5%) OA patient
DNA samples. Significantly more often genomic sequences
of both viruses were detected in synovial tissue DNA sam-
ples of RA patients (3/7, 42.9%) than in OA patients (3/54,
5.6%; p = 0.0166; OR 12.8, 95% CI: 1.9 to 84.9). Three of
seven (42.9%) synovial tissue DNA samples of RA and
34/54 (63.0%) of OA patients lacked detectable HHV-6 and
HHV-7 genomic sequences (Table 2).
Presence of HHV-6 immunoreactivity in synovial tis-
sues. Cells labeled by the anti-HHV-6 antibody for HHV-6
A and B strains displayed a brown cytoplasmic staining pat-
tern. Expression of HHV-6 in synovial tissues was demon-
strated in HHV-6-positive RA and OA patients enrolled for
the study and estimated by histopathology (Fig. 1A). This
HHV-6-immunoexpression was moderate and/or strong.
Examination of the occurrence and localisation of HHV-6-
positive cells by immunohistochemistry showed their pres-
ence in the synovial lining, which often was stratified into
multiple layers, but still intermixed with synoviocytes dis-
playing immunonegativity (Fig. 1B). Some RA and OA
cases demonstrated HHV-6 immunopositivity along an inti-
mal endothelial aspect of small blood vessels. Strong
HHV-6 expression was found in large foam-like vascular
wall cells (in one case of OA).
RA clinical parameters, treatment and frequency of
complications in RA patients with different activity
phase or without HHV-6 and HHV-7 infection. The
counts of painful joints and duration of morning stiffness, as
well as frequency of different complications — polyneuro-
pathy, rheumatoid nodules, osteoporosis, cervical spine
damage, sicca syndrome and scleritis, in RA patients with
different activity phases of HHV-6 and HHV-7 infection or
without activity was very similar (Tables 3, 4). However,
morning stiffness was significantly lower in RA patients
with active HHV-6 infection than in patients with latent
HHV-6 infection (p = 0.02; 95% CI: 16.0 to 178.0).
Myopathic syndrome was detected significantly less often
in RA patients with active HHV-7 infection, than in patients
with latent HHV-6 infection (p = 0.0117; 95% CI: 0.1 to
0.7) and patients without HHV-6 and HHV-7 infection (p =
0.0158; 95% CI: 0.1 to 0.8). More serious complication as
scleritis was observed in RA patients with only latent
HHV-7, and cervical spine damage was observed in RA pa-
tients with only latent HHV-6 and HHV-7 infection (Table
3). The detection frequency of HHV-6 and/or HHV-7 active
and latent infection didn’t differ in RA patients receiving or
not receiving DMARDs. HHV-6 and HHV-7 infection fre-
T a b l e 2
FREQUENCY OF VIRUS-SPECIFIC DNA IN SYNOVIAL TISSUES’
AND SYNOVIAL FLUID DNA SAMPLES OF RA AND OA PATIENTS
Patients
Viral sequence in DNA samples















2/6 2/6 1/6 0/7 1/7 3/7
OA
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0/34 10/34 3/34 0/54 17/54 3/54
A B
Fig. 1. A. Rheumatoid synovitis revealing lymphocytic infiltration and diffuse macrophage infiltration demonstrated with the anti-CD68 antibody. Original
magnification x 250; B. Multiple layers of hyperplastic synoviocytes displaying HHV-6 immunoreactivity. Original magnification × 250.
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quency was lower in single MTX users in comparison with
“DMARDs on” group (p = 0.0555; OR 5.3, 95% CI: 0.9 to
30.2) and “DMARDs off” group (p = 0.0737; OR 0.2, 95%
CI: 0.03 to 1.1) without statistical significance. Interest-
ingly, HHV-6 and also HHV-7 infection reactivation were
not observed in single methotrexate and in biologic treat-
ment groups. No increase in appearance of complications
such as polyneuropathy, myopathic syndrome, rheumatoid
nodules, osteoporosis and sicca syndrome was observed in
RA patients with active HHV-6 and/or HHV-7 infection
(Table 3).
Clinical parameters did not diverge in OA patients with dif-
ferent activity phases of HHV-6 and HHV-7 infection.
Disease activity and aggressiveness laboratory parame-
ters and cytokine levels of RA and OA patients as well
as radiological stage of RA patients with and without
different activity phase of HHV-6 and HHV-7 infections.
There was no significant correlation between HHV-6 and/or
HHV-7 infection activity stage, and DAS28 and ESR indi-
ces in RA patients. RA patients had moderate disease activ-
ity (DAS28 score 3.2–5.1) in all HHV-6 and/or HHV-7 in-
fection groups. CRP and ESR mean levels were higher than
the normal range in all RA patients groups. Of the disease
activity indexes, the mean CRP level was significantly
higher in the patient group with latent HHV-7 infection than
in the patient group with active HHV-7 infection (p =
0.0031, 95% CI: 5.3 to 24.4).
In OA patients, the mean CRP level was higher in the pa-
tients group with latent HHV-7 infection than in patients
group without HHV-6 and HHV-7 infection (p = 0.0488,
95% CI: 0.04 to 14.6), but no differences occurred in the
presence of the ESR medium level in OA patients with vari-
ous activity phases of HHV-6 and HHV-7 infection.
Both RA aggressiveness indexes were higher than normal
range, but without statistical significance among groups
with HHV-6 and/or HHV-7 infection, and the indexes were
not related to the infection activity phase (Table 4), also if
RA patients without HHV-6 and HHV-7 infection were
used as control group (Fig. 2).
We did not find significant difference of radiographycal
stage in groups of RA patients with various HHV-6 and
HHV-7 infection activity phases.
We observed elevated levels of RF and anti-CCP in OA pa-
tients, but the OA patients with positive anti-CCP level do
not comply with the RA diagnostic criteria.
IL-6 mean level was significantly lower in RA patients with
active HHV-6 than in patients with latent HHV-6 infection
(p = 0.0478, 95% CI: 0.9 to 153.7). No significant differ-
ences in the mean level of TNF- and IL-17 were observed
in RA patients, nor in the mean level of all analysed
cytokines in OA patients with different activity phases of
HHV-6 and HHV-7 infection (Table 5, Fig. 2). The level of
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Polyneuropathy 5/10 3/15 4/13 7/42 2/13
Myopathic syndrome 3/10 8/15 1/13 15/42 6/13
Rheumatoid nodules 3/10 1/15 1/13 3/42 1/13
Osteoporosis 4/10 6/15 0/13 8/42 2/13
Cervical spine damage 0/10 2/15 0/13 1/42 0/13
Sicca syndrome 2/10 0/15 2/13 2/42 0/13
Scleritis 0/10 0/15 0/13 1/42 0/13
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TNF- tended to be higher in RA patients with active
HHV-6 and/or HHV-7 infection than in the other groups.
DISCUSSION
Viruses and viral infections are considered to be the main
risk factors for autoimmune disease development (espe-
cially for individuals with genetic predisposition). The de-
velopment of several autoimmune pathologies, including
multiple sclerosis, autoimmune connective tissue diseases,
and Hashimoto thyroiditis, are linked to HHV-6A/B infec-
tion (Chapenko et al., 2003; Nora-Krukle et al., 2011;
Caselli et al., 2012; Broccolo et al., 2013). It is also be-
lieved that human parvovirus B19, as an aetiological or
co-efficient factor, is involved in the development of dis-
eases such as RA, systemic lupus erythematosus, anti-phos-
pholipid syndrome, systemic sclerosis and vasculitis. Our
previous research has demonstrated linkage of parvovirus
B19 to RA and association of the clinical development of
the disease to infectious activity of the virus (Kozireva et
al., 2008; Kakurina et al., 2015).
T a b l e 5















































Fig. 2. Levels of RF (A), anti-CCP (B), TNF- (C) and IL-6 (D) in RA patients with various persistent HHV-6 and HHV-7 infection activity phases. RA no
infection group represents healthy control.
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In this study we assess the possible association of HHV-6
and HHV-7 infection with RA and OA aetiopathogenesis.
Significantly higher prevalence of HHV-6 DNA has been
observed in RA patient sera, compared with healthy control
individuals (Alvarez-Lafuente et al., 2009) and OA patients
may have risk of EBV transmission or reactivation (Rollin,
2009). We did not find significant difference in prevalence
of persistent HHV-6 and HHV-7 as well as in reactivation
of HHV-6 and HHV-7 infection in RA and OA patients and
healthy control groups. Despite similar frequency of persis-
tent HHV-6 and/or HHV-7 infection in RA and OA patient
groups by nPCR, HHV-6 DNA was detected significantly
more frequently in synovial fluid of the RA patients group
than in the OA patient group (p = 0.02, OR 38.3, 95% CI:
1.6 to 932.3). In synovial tissues of RA and OA patients, no
single HHV-6 infection was found and there was no differ-
ence in the frequency of HHV-7 DNA in synovial tissues of
both patient groups, but the frequency of concurrent HHV-6
and HHV-7 infection was significantly higher in synovial
tissues of RA patients than in that of OA patients (p = 0.02,
OR 12.8, 95% CI: 1.9 to 84.9). HHV-6 reactivity was con-
firmed in all PCR-positive RA cases by immunohistochem-
istry, but this does not exclude the presence of concurrent
HHV-7 infection and possible detection of viral antigens.
Demonstration of HHV-6 and/or HHV-7 DNA within the
synovial joint cavity might suggest viral replication associ-
ated either with the primary immune disturbances of RA or
with the immune depression produced by immunosuppres-
sive drugs.
Effect of HHV-6 and/or HHV-7 on RA clinical parameters
was different. There was no significant difference in the
number of painful and swollen joints as well as pain sever-
ity in RA patients with HHV-6 and HHV-7 infection, de-
pending on the activity phase of infection. Occurrence of
morning stiffness was significantly lower in RA patients
with active HHV-6 infection than in patients with latent
HHV-6 infection. This can be explained by the treatment
regimen — six RA patients with active HHV-6 received the
severe immunosuppressive drug glucocorticoid with or
without sDMARDs and only two patients received nonspe-
cific treatment with NSAIDs. No significant difference was
observed in disease clinical parameters in OA patients with
various phases of HHV-6 and HHV-7 infection activity.
It is known that treatment with immunosuppressive drugs
can influence reactivation of chronic viral infection (Vassi-
lopoulos and Calabrese, 2007; Nard et al., 2015), but in our
study there was no effect of treatment regimen on preva-
lence of active HHV-6 and HHV-7 infection. No infection
reactivation in RA patients groups with single methotrexate
and biologic treatment was observed. These drugs are se-
vere immunosuppressants that are prescribed in the case of
severe active RA and possibly they can block reactivation
of HHV-6 and HHV-7 infection. Previous studies did not
find correlation between RA treatment and prevalence of
HHV-6 DNA in sera (Alvarez-Lafuente et al., 2005), nor
significant association of the presence of cytomegalovirus
and Epstein-Barr virus specific antibodies with the age, sex,
disease duration (from symptom onset), RF status, ACPA
status, pain, fatigue, DAS28, HAQ disability, the SF-36
physical or mental component summary scores, or treatment
with methotrexate, biologic response modifiers, or predni-
sone (Davis et al., 2012). Other authors have accented the
role of viral infection as a “second hit” acting in the pres-
ence of circulating ACPA and determining the transition
from the pre-RA phase to chronic synovitis (van de Sande
et al., 2011).
There was no significant correlation between HHV-6 and
HHV-7 infection and frequency of complications, such as
polyneuropathy, rheumatoid nodules, osteoporosis, cervical
spine damage, sicca syndrome and scleritis. However, seri-
ous RA complications like cervical spine damage and
scleritis were observed only in patients with latent HHV-6
and/or HHV-7 infection. Also, the late RA sign myopathic
syndrome was observed significantly often in RA patients
with latent HHV-7 infection. This suggests that HHV-6/-7
infection can promote the disease progression. Analysis of
the RA course severity suggests also high prevalence of RA
complications in the patients group with active single
HHV-6 infection as well as a more severe radiographic
stage in RA patients with active concurrent HHV-6 and
HHV-7 infection.
Several studies reported that anti-CMV-seropositive RA pa-
tients showed radiographic evidence of more advanced joint
destruction (Davis et al., 2012; Pierer et al., 2012). We did
not observe significant differences in radiographical stage
among RA patients with different HHV-6 and HHV-7 in-
fection stage.
The mean level of CRP was significantly higher in RA pa-
tients with latent HHV-7 infection, compared to that in pa-
tients with active HHV-7 infection. Almost all RA patients
with active HHV-7 infection had received glucocorticoids
and/or sDMARDs, which could reduce disease activity. Pre-
vious work also suggested lack of correlation of HHV-6 in-
fection reactivation and RA activity (Broccolo et al., 2013).
The mean levels of RA aggressiveness parameters RF and
anti-CCP did not differ in RA patients with different
HHV-6 and/or HHV-7 infection activity phases.
In OA patients, only the CRP mean level was significantly
higher in patients group with latent HHV-7 infection, com-
pared with that in the patients group without HHV-6 and
HHV-7 infection; no significant differences in presence of
ESR medium level was observed between OA patients with
various activity phases of HHV-6 and HHV-7 infection.
This shows that effect of HHV-6 and HHV-7 infection on
OA disease activity is low.
Despite the lack of significant correlation between fre-
quency of persistent single HHV-6, single HHV-7, and con-
current HHV-6 and HHV-7 infection, as well as its reactiva-
tion and RA clinical course, we found that both active and
latent HHV-6 and/or HHV-7 infection increased RA activ-
ity and progression in several clinical and laboratory pa-
172 Proc. Latvian Acad. Sci., Section B, Vol. 70 (2016), No. 4.
rameters. This suggests that HHV-6 and/or HHV-7 infec-
tion has effect on disease activity and aggressiveness, and
that reactivation of these viruses may be a consequence of
immunosuppressive treatment. 80.9% RA patients with
HHV-6 and/or HHV-7 reactivation received glucocorti-
coids, methotrexate and leflunomide in different combina-
tions or separately, which are strong immunosuppressants.
Analysis of the severity of the course of RA suggests also
high prevalence of RA complications in the patients group
with active single HHV-6 infection and also a more severe
radiographical stage in RA patients with active concurrent
HHV-6 and HHV-7 infection. HHV-6 and HHV-7 infection
markers also were found in synovial fluid and synovial tis-
sues of affected joints of RA patients, suggesting their in-
volvement in RA aetiopathogenesis.
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CILVÇKA HERPESVÎRUSA 6 UN 7 INFEKCIJAS IETEKME UZ REIMATOÎDÂ ARTRÎTA KLÎNISKO GAITU
Reimatoîdais artrîts (RA) ir hroniska sistçmiska autoimûna iekaisuma slimîba, kas skar galvenokârt locîtavas, izraisot simetrisku hronisku
progresçjoðu aseptisku sinovîtu un vçlîni erozîvi destruktîvas izmaiòas. Vîrusi un vîrusu infekcijas tiek uzskatîti par vienu no galvenajiem
riska faktoriem autoimûno slimîbu attîstîbâ (îpaði personâm ar ìençtisku predispozîciju). Ðî pçtîjuma mçríis bija noskaidrot persistentas
HHV-6 un HHV-7 infekcijas sastopamîbu un aktivitâtes fâzi slimniekiem ar RA, osteoartrîtu (OA) un veselâm personâm. Mçs noteicâm arî
HHV-6 un HHV-7 infekcijas ietekmi uz RA aktivitâti, agresivitâti, radioloìisko stadiju un slimîbas komplikâciju bieþumu, kâ arî vîrusu
infekcijas maríieru klâtbûtni RA pacientu skarto locîtavu sinoviâlajâ ðíidrumâ un sinoviâlajos audos. Neraugoties uz to, ka netika
konstatçta ticama sakarîba starp persistentu HHV-6, persistentu HHV-7, persistentu abu vîriusu dubultinfekciju un RA klînisko gaitu, mçs
noteicâm, ka gan aktîva, gan latenta HHV6 un/vai HHV-7 infekcija pçc vairâkiem klîniskiem un laboratoriskiem parametriem paaugstina
RA aktivitâti un progresiju. Turklât vîrusu infekcijas maríieri tika atrasti RA pacientu skarto locîtavu sinoviâlajâ ðíidrumâ un sinovija
audos. Tas liek domât, ka HHV-6 un/vai HHV-7 infekcija ietekmç slimîbas aktivitâti un agresiju, bet ðo vîrusu reaktivâciju var veicinât
imunosupresîvo medikamentu lietoðana.
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